Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and CIBINQO. Developed by Pfizer, abrocitinib has received marketing authorization for abrocitinib in adults with moderate-to-severe atopic dermatitis from the Central Drugs Standard Control Organization (CDSCO). It is also approved by the USFDA, European Medicines Agency (EMA), and other regulatory agencies.
Related Keywords
India , Japan , China , Alok Malik , Meenakshi Nevatia , European Medicines Agency , Pfizer , Central Drugs Standard Control Organization , India Formulations , Abrocitinib , Atopic Dermatitis , Glenmark ,
comparemela.com © 2020. All Rights Reserved.